| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 04/18/2002 | CA2425835A1 Methods and compositions for nucleic acid delivery |
| 04/18/2002 | CA2425779A1 Compositions that inhibit proliferation of cancer cells |
| 04/18/2002 | CA2425650A1 Methods for the treatment of a traumatic central nervous system injury |
| 04/18/2002 | CA2425610A1 Intracellular delivery of biological effectors by novel transporter peptide sequences |
| 04/18/2002 | CA2425508A1 Targeted therapeutic agents |
| 04/18/2002 | CA2425407A1 Protecting therapeutic compositions from host-mediated inactivation |
| 04/18/2002 | CA2425035A1 Medicinal aerosol formulations |
| 04/18/2002 | CA2424967A1 Complexes for transferring nucleic acids into cells |
| 04/18/2002 | CA2424928A1 Encased food product with contrasting components |
| 04/18/2002 | CA2424785A1 Mediators of hedgehog signaling pathways, compositions and uses related thereto |
| 04/18/2002 | CA2424444A1 Topical antibiotic composition for treatment of eye infection |
| 04/18/2002 | CA2424055A1 Medication delivery devices |
| 04/18/2002 | CA2423850A1 Therapeutic antibodies |
| 04/17/2002 | EP1197553A1 Antisense nucleic acid against alphaV integrin |
| 04/17/2002 | EP1197496A1 Novel peptides |
| 04/17/2002 | EP1197222A2 A stabilized pharmaceutical formulation comprising growth hormone and histidine |
| 04/17/2002 | EP1197221A1 Preparations stabilized over long time |
| 04/17/2002 | EP1197215A2 Anthelmintic compositions |
| 04/17/2002 | EP1197209A1 Percutaneously absorbable preparations |
| 04/17/2002 | EP1197208A1 Sustained release compositions, process for producing the same and use thereof |
| 04/17/2002 | EP1197207A2 Stable compositions for parenteral administration |
| 04/17/2002 | EP1196618A2 Novel vector complexes and their use in gene therapy |
| 04/17/2002 | EP1196495A1 Freeze-dried agent containing paramylon, production and utilization thereof |
| 04/17/2002 | EP1196444A1 Peptides that lower blood glucose levels |
| 04/17/2002 | EP1196443A2 Erythropoietin conjugates with polyethylenglycol |
| 04/17/2002 | EP1196430A2 Purification and stabilization of peptide and proteins in pharmaceutical agents |
| 04/17/2002 | EP1196383A1 Process for preparing amlodipine benzenesulphonate |
| 04/17/2002 | EP1196196A2 Conjugate for mediating cell, compartment or membrane-specific transport of active substances |
| 04/17/2002 | EP1196195A1 Nasogastric enteral formulations |
| 04/17/2002 | EP1196189A2 Multiple agent diabetes therapy |
| 04/17/2002 | EP1196187A1 Keratinocyte growth factor-2 formulations |
| 04/17/2002 | EP1196175A1 Pharmaceutical tablets |
| 04/17/2002 | EP1196157A1 Amphiphilic drug-oligomer conjugates with hydrolyzable lipophile components and methods for making and using the same |
| 04/17/2002 | EP1196156A2 Transnasal anticonvulsive compositions and modulated process |
| 04/17/2002 | EP1196151A1 Transdermal therapeutic system for administering a calcium antagonist |
| 04/17/2002 | EP1196149A1 BIODEGRADABLE POLY(ALKYLENE OXIDE)-POLY(p-DIOXANONE) BLOCK COPOLYMER SOLUBLE IN ORGANIC SOLVENTS, AND DRUG DELIVERY COMPOSITION COMPRISING SAME |
| 04/17/2002 | EP1196148A1 Process for microencapsulation of water soluble substances |
| 04/17/2002 | EP1196147A1 Oral liquid compositions |
| 04/17/2002 | EP1196146A2 Powder particles with smooth surface for use in inhalation therapy |
| 04/17/2002 | EP1196145A1 Methods and apparatus for preparation of lipid vesicles |
| 04/17/2002 | EP1196144A2 A liposome composition having resistance to freeze/thaw damage |
| 04/17/2002 | EP1196143A1 Method for releasing an agent from a red blood cell |
| 04/17/2002 | EP1196138A1 Pre-formed gel sheet |
| 04/17/2002 | EP1196136A1 Compositions comprising organosiloxane resins for delivering oral care substances |
| 04/17/2002 | EP1196135A1 Compositions comprising organosiloxane resins for delivering oral care substances |
| 04/17/2002 | EP1196043A1 An effervescent green tea extract formulation |
| 04/17/2002 | EP1196034A1 Antiparasitic formulation |
| 04/17/2002 | EP1121145B1 Insulin preparations for pulmonary delivery containing menthol |
| 04/17/2002 | EP1119315A4 Delivery of phosphoinositide polyphosphates into cells |
| 04/17/2002 | EP1028730B1 Compositions of lipid lowering agents |
| 04/17/2002 | EP1019037B9 Medicament containing delta-aminolevulinic acid |
| 04/17/2002 | EP1007561B1 Novel conjugates of opioids and endogenous carriers |
| 04/17/2002 | EP0994726B1 Compositions suitable for delivery of genes to epithelial cells |
| 04/17/2002 | EP0986404B1 Gene therapy delivery system for targeting to endothelia |
| 04/17/2002 | EP0956010B1 Pharmaceutical microspheres of valproic acid for oral administration |
| 04/17/2002 | EP0901378B1 Pharmaceutical compositions containing cyclosporine and a carrier comprising at least an ester of alpha-glycerophosphoric acid |
| 04/17/2002 | EP0886652B1 Pulmonary surfactant peptide solubilization process |
| 04/17/2002 | EP0873129B1 Anion exchange resin-containing tablets |
| 04/17/2002 | EP0863767B1 Powdery iodine complexes |
| 04/17/2002 | EP0799035B1 Emulsion suitable for administering a sphingolipid and use thereof |
| 04/17/2002 | EP0794790B1 Localized delivery of factors enhancing survival of transplanted cells |
| 04/17/2002 | EP0793506B1 Cellular and serum protein anchors and conjugates |
| 04/17/2002 | EP0744947B1 Modified-release metronidazole compositions and methods for making and using same |
| 04/17/2002 | EP0742722B1 Method for increasing bioavailability of oral pharmaceutical compositions |
| 04/17/2002 | EP0740550B1 Use of mometasone furoate for treating airway passage and lung diseases |
| 04/17/2002 | EP0568651B1 Biodegradable polymer blends for drug delivery |
| 04/17/2002 | CN1345336A Antibody and chemokine constructs and their use for treating autoimmune diseases |
| 04/17/2002 | CN1345333A Echinocandin/carbohydrate complexes |
| 04/17/2002 | CN1345245A Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| 04/17/2002 | CN1345235A Granulate with high content of L-carnitine or alkanoyl L-carnitine |
| 04/17/2002 | CN1345233A Pregelatinized starch in controlled release formulation |
| 04/17/2002 | CN1345232A Hydrogel particle formulations |
| 04/17/2002 | CN1345221A Hair treatment compositions comprising C20 or higher unsaturated fatty acid polyester of cyclic polyols |
| 04/17/2002 | CN1345213A Transdermal therapeutic system with nicotine and addition of monoterpene ketones |
| 04/17/2002 | CN1344755A Prep. of degradable polymer, pharmaceutical composition containing the same and its use |
| 04/17/2002 | CN1344565A Fucoidin ester as antiviral immunoregulator and its prepn |
| 04/17/2002 | CN1082970C Low-odor, higher molecular weight polyeher polyols, process for producing them and their use |
| 04/17/2002 | CN1082822C Cosmetic and skin-useful composition containing water from hot spring or mineral water and agent against acne and oldening |
| 04/17/2002 | CN1082821C Antibody cojugates |
| 04/17/2002 | CN1082818C 1 alpha, 24-(OH)2-V D3-emulsion composition |
| 04/17/2002 | CN1082817C Corticosteroid-containing pharmaceutical compositions |
| 04/17/2002 | CN1082813C Stabized solutions of platinum (II) antitumor agents |
| 04/16/2002 | US6372794 Antiarthritic agents |
| 04/16/2002 | US6372760 Stabilized composition comprising antidementia medicament |
| 04/16/2002 | US6372755 Includes at least one of a water soluble antioxidant, a fat soluble antioxidant, a synergist, a sugar and a surfactant |
| 04/16/2002 | US6372753 Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists |
| 04/16/2002 | US6372738 Cytotoxic agents comprising taxanes and their therapeutic use |
| 04/16/2002 | US6372728 Formulation for treatment of osteoporosis |
| 04/16/2002 | US6372716 Freeze dried mixture with glycine, polysorbate, sucrose, and histidine; storage stability |
| 04/16/2002 | US6372712 Complex of peptidyl-propyl cis/trans isomerase and drug such as rapamycin, cyclosporin a, fk-506, or other antibiotic |
| 04/16/2002 | US6372499 Transfection efficiency |
| 04/16/2002 | US6372491 To induce vascularization |
| 04/16/2002 | US6372267 Cocoa solids prepared by heating, pressing, recovering partially defatted cocoa solids which contain cocoa polyphenols including cocoa procyanidins |
| 04/16/2002 | US6372264 Method of reducing calcified arterial plaque buildup and cellular malfunction and for balancing ionic calcium |
| 04/16/2002 | US6372260 Incorporation of active substances in carrier matrixes |
| 04/16/2002 | US6372255 Tablet for instant and prolonged release of one or more active substances |
| 04/16/2002 | US6372253 Rapidly disintegrating methylcellulose tablets |
| 04/16/2002 | US6372252 Containing quantity of medicine in immediate release layer and second portion in release-delay matrix of hydrophilic polymer and water insoluble polymer |
| 04/16/2002 | US6372251 Bioavailability |
| 04/16/2002 | US6372250 Non-invasive gene targeting to the brain |